Company Description
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib.
Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
| Country | United States |
| Founded | 2011 |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 87 |
| CEO | Brian Sullivan |
Contact Details
Address: 16305 36th Avenue North, Suite 100 Minneapolis, Minnesota 55446 United States | |
| Phone | (763) 392-0767 |
| Website | celcuity.com |
Stock Details
| Ticker Symbol | CELC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001603454 |
| CUSIP Number | 15102K100 |
| ISIN Number | US15102K1007 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Brian F. Sullivan | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Lance G. Laing Ph.D. | Co-Founder, Chief Science Officer, Vice President, Secretary and Director |
| Vicky Hahne CPA | Chief Financial Officer |
| Brent Eilefson | General Counsel |
| Sheri Smith | Acting Head of Clinical Operations |
| Igor Gorbatchevsky M.D. | Chief Medical Officer |
| Eldon C. Mayer III, M.B.A. | Chief Commercial Officer |
| Dr. Charlotte Moser M.B.A., M.D., M.Sc., Ph.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2025 | SCHEDULE 13G/A | Filing |
| Apr 1, 2025 | ARS | Filing |
| Apr 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 1, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |